Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

65992 1510824253HCLSReviewUkraineNovember2017.pdf
Energy Boardroom

Roche gets thumbs up for CLL use of Gazyvaro in EU

23.05.2014 / Fierce Pharma

Gazyva, Roche's successor to Rituxan, is already approved in the U.S. for first-line use on chronic lymphocytic leukemia (CLL) and appears poised for the same in Europe. The EU Committee for Medicinal Products for Human Use (CHMP) today recommended it for approval there.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: